drugset / Trial / NCT02976194

Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy

NCT02976194

NaSingle-groupOpen-labelBasic science

Summary

Changes of intraocular cytokines including vascular endothelial growth factor (VEGF) will be measured in recurrence of polypoidal choroidal vasculopathy (PCV) during treatment of ranibizumab.

Timeline

Start
2016-11-22
Primary completion
2019-11
Completion
2020-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal